. Author manuscript; available in PMC: 2008 Jun 4.

Published in final edited form as: J Neural Transm (Vienna). 2008 Jan 11;115(5):745–753. doi: 10.1007/s00702-007-0004-5

Table 2.

Average D₂ receptor occupancies and plasma levels obtained for each drug treatment group, and for the peak and trough subgroups

Treatment group (mg/kg/day)	Average D₂ receptor occupancy^a	Average D₂ receptor occupancy^a (peak + trough)	Average plasma drug levels (ng/ml)	Average plasma levels (ng/ml) (peak + trough)
Haloperidol:
1.5 Peak	85.78 ± 3.69		5.02 ± 1.96
1.5 Trough	68.43 ± 5.99	77.11 ± 10.54	1.84 ± 0.53	3.43 ± 2.26
2.0 Peak	86.43 ± 4.66		3.36 ± 1.58
2.0 Trough	70.94 ± 7.43	78.68 ± 10.46	1.68 ± 0.43	2.52 ± 1.51
Clozapine:
20 Peak	16.07 ± 11.79		8.6 ± 1.02
20 Trough	−13.32 ± 10.85	1.37 ± 19.84	1.8 ± 3.6	5.25 ± 4.40
40 Peak	26.93 ± 18.42		29.8 ± 17.27
40 Trough	−6.33 ± 18.23	10.30 ± 26.09	6.0 ± 3.10	17.9 ± 18.12
Olanzapine:
2 Peak	32.50 ± 9.26		1.54 ± 0.67
2 Trough	12.78 ± 11.78	22.64 ± 15.47	0.16 ± 0.32	0.87 ± 0.95
4 Peak	42.20 ± 19.69		7.58 ± 4.95
4 Trough	36.98 ± 14.59	39.88 ± 18.88	1.24 ± 1.38	4.81 ± 5.22
5 Peak	44.14 ± 13.03		8.62 ± 2.87
5 Trough	33.44 ± 7.86	39.39 ± 12.99	0.8 ± 0.26	5.13 ± 4.72

D₂ receptor occupancy values are shown as the percentage of control animals. In human patients clinically relevant receptor occupancy values are 65–80% for haloperidol and olanzapine, and 45–65% for clozapine (Kapur et al. 2003)